Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the techni...

Full description

Bibliographic Details
Main Authors:	Foroni, L, Wilson, G, Gerrard, G, Mason, J, Grimwade, D, White, H, de Castro, D, Austin, S, Awan, A, Burt, E, Clench, T, Farruggia, J, Hancock, J, Irvine, A, Kizilors, A, Langabeer, S, Milner, B, Nickless, G, Schuh, A, Sproul, A, Wang, L, Wickham, C, Cross, N
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
by: Cross, N, et al.
Published: (2018)

Sequential quantitative minimal residual disease in BCR-ABL positive acute lymphoblastic leukaemia: Differential observations between major and minor fusion gene rearrangements and variation due to source material
by: Gerrard, G, et al.
Published: (2004)

No Benefit of BCR-ABL1 Screening in Polycythemia
by: STEPHEN E. LANGABEER
Published: (2016-07-01)

Targeting BCR-ABL1-positive leukaemias: a review article
by: Steven Leak, et al.
Published: (2023-01-01)

The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia
by: Renren Zheng, et al.
Published: (2024-06-01)

Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia
by: Sarah L. McCarron, et al.
Published: (2013-01-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche
by: Amy Dawson, et al.
Published: (2024-02-01)

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
by: Philippa C. May, et al.
Published: (2023-07-01)

No association between BCR-ABL1 fusion genes and clinical features of acute lymphoblastic leukaemia in Ghanaian patients
by: Victor Obeng Ofori, et al.
Published: (2020-10-01)

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
by: Berke, Z, et al.
Published: (2000)

BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients
by: Kizilors, A, et al.
Published: (2019)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
by: Baum Karina J, et al.
Published: (2008-06-01)

EVI1 expression in acute myeloid leukaemia.
by: Langabeer, SE, et al.
Published: (2001)

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
by: Ilaria Iacobucci, et al.
Published: (2007-03-01)

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
by: Chengwu Zeng, et al.
Published: (2024-10-01)

Co-expression of the CBFβ-MYH11 and BCR-ABL fusion genes in chronic myeloid leukaemia / Coexistenţa genelor de fuziune CBFβ-MYH11 şi BCR-ABL în leucemia mieloidă cronică
by: Popescu Roxana, et al.
Published: (2015-06-01)

Genomic amplification of <it>BCR/ABL1 </it>and a region downstream of <it>ABL1 </it>in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
by: Virgili Anna, et al.
Published: (2010-09-01)

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases
by: Anna Płotka, et al.
Published: (2023-07-01)

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
by: Abdullah Aljedai, et al.
Published: (2015-01-01)

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
by: Stephen E. Langabeer, et al.
Published: (2023-01-01)

The other Achilles’ heel of BCR-ABL1
by: Kim De Keersmaecker
Published: (2012-01-01)

An In-house Method for Molecular Monitoring of BCR-ABL
by: Hakkı Ogun Sercan, et al.
Published: (2012-12-01)

Smart applications of bionanosensors for BCR/ABL fusion gene detection in leukemia
by: Karen Y.P.S. Avelino, et al.
Published: (2017-10-01)

p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
by: Afsar A. Mian, et al.
Published: (2012-02-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2018-03-01)

LMC y detección del gen de fusión BCR/ABL
by: C. G. Artigas Allaire
Published: (2006-04-01)

Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease
by: Úna Bhreathnach, et al.
Published: (2022-01-01)

Detection of ABL1 deletion without BCR-ABL rearrangement in ETP-ALL
by: Ahmed Makboul, et al.
Published: (2024-10-01)

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL
by: Jane R. Engler, et al.
Published: (2011-02-01)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
by: Saskia Maletzke, et al.
Published: (2022-01-01)

Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population
by: Jew Win Kuan, et al.
Published: (2024-06-01)

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach
by: Caroline Busch, et al.
Published: (2023-11-01)

Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs
by: Dixon, A, et al.
Published: (2011)

Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
by: Dixon, A, et al.
Published: (2012)